MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
News Sep 08, 2009
MorphoSys AG has announced that Bayer Schering Pharma AG, Germany has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived antibody-drug conjugate (ADC) in the therapeutic area of oncology. This achievement marks a significant milestone within the Bayer Schering Pharma alliance and triggers a payment to MorphoSys.
"Today's news underlines how important our core technology is to the pharmaceutical industry's drug pipeline," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "We now have clinical trials of HuCAL-based antibodies ongoing with four different pharmaceutical companies. The output of our partners' application of MorphoSys's proprietary HuCAL technology is becoming an increasingly visible and important value driver for our Company."
The current program is directed against the target molecule MN, also known as Carbonic Anhydrase or CA IX for short, a tumor associated antigen expressed in many tumor types under hypoxic conditions. The antibody is the first fully human HuCAL-based ADC to enter clinical trials.
ADCs comprise antibodies linked to cytotoxic drugs, and combine the targeting properties of the antibody with the cell-destroying effect of the conjugated drug. In the present program, the HuCAL-derived antibody-drug conjugate incorporates technology licensed to Bayer Schering Pharma from Seattle Genetics.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE